UK-based Stabilitech has signed a manufacturing deal with New Zealand-based BioCell for its oral, investigational Covid-19 vaccine, OraPro-COVID-19.
Stabilitech chairman Wayne Channon explained: “After a successful recent fundraising round, this signed agreement represents a crucial next step for OraPro-COVID-19.
“It brings us closer to providing a vaccine that gives both mucosal and systemic immunity to Covid-19.
This will target the virus exactly where we catch it: in the mucous membranes of the mouth, nose, throat and even the eyes.
By taking this approach, we believe OraPro-COVID-19 could prove to provide the fastest route to widespread global immunity, turning the tide on the pandemic.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData